P450 enzyme expression patterns in the NCI human tumor cell line panel

Area of Science:

• Pharmacology
• Biochemistry
• Oncology

Background:

• The National Cancer Institute's 60 human tumor cell line panel is a key resource for anticancer drug screening.
• Cytochrome P450 (P450) enzymes play crucial roles in drug metabolism, influencing therapeutic efficacy and toxicity.
• Understanding P450 expression in tumors is vital for predicting drug response.

Purpose of the Study:

• To characterize Cytochrome P450 (P450) enzyme expression patterns in a panel of 60 human tumor cell lines.
• To investigate the correlation between P450 activity and cytotoxicity of various anticancer agents.
• To explore the potential of P450 enzyme profiling for predicting drug sensitivity and resistance.

Main Methods:

• Assessed P450 and P450 reductase activity using specific substrates (e.g., 7-benzyloxyresorufin, 7-ethoxycoumarin).
• Determined cell line-specific P450 enzyme patterns.
• Employed the COMPARE pattern-matching program to correlate P450 activity with cytotoxicity data for anticancer agents.

Main Results:

• All 60 cell lines exhibited significant P450 and P450 reductase activity.
• Significant negative correlations were found between P450 metabolism and chemosensitivity for several anticancer agents, indicating P450-mediated drug inactivation.
• P450-dependent inactivation was suggested for alkylating agents and topoisomerase inhibitors.

Conclusions:

• P450 enzyme profiling provides insights into drug sensitivity and resistance mechanisms within the NCI tumor cell panel.
• Correlations suggest P450 enzymes contribute to the inactivation of certain anticancer drugs.
• This profiling may facilitate the identification of anticancer agents whose activity is modulated by P450 metabolism.